Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
38.033,47 +404,99 (+1,08%) EUR/USD
1,0727 -0,0006 (-0,05%) Bitcoin EUR
59.905,00 +72,62 (+0,12%) CMC Crypto 200
1.383,82 +1,24 (+0,09%)
MediciNova, Inc. (MNOV)
Dopo ore:
| Chiusura precedente | 1,3550 |
| Aperto | 1,3300 |
| Denaro | 0,9432 x 200 |
| Lettera | 1,7200 x 200 |
| Min-Max giorno | 1,3200 - 1,3700 |
| Intervallo di 52 settimane | 1,2600 - 2,6600 |
| Volume | |
| Media Volume | 49.791 |
| Capitalizzazione | 64,741M |
| Beta (5 anni mensile) | 0,69 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,1700 |
| Prossima data utili | 10 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 17,00 |
GlobeNewswireMediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
LA JOLLA, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS). Once issued, the pa
- GlobeNewswire
MediciNova Receives Gene Therapy Milestone Payment
LA JOLLA, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi. The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therap
- GlobeNewswire
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
LA JOLLA, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the results of the nonclinical studies conducted under its contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Servi
